TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06741735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVU fetal monitoring system
Description: INVU fetal monitoring system allows for at-home non-stress testing as opposed to the typical in-clinic testing
Study: NCT06741839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy guided pleural biopsy using medical thoracoscopy
Description: After the completion of the routine thoracoscopic examination, the biopsy location was determined based on the results of chest CT/ ultrasound. The benign and malignant states of pleural lesions were explored by nCLE and image records were collected. Then, the biopsy tissues were collected under the guidance of nCLE.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plerual biopsy using medical thoracoscopy
Description: After the completion of the routine thoracoscopic examination, the biopsy location was determined according to the results of chest CT/ ultrasound, and random pathological biopsy was performed, and biopsy tissues were collected by biopsy forceps.
Study: NCT06742424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 antibody
Description: 1200mg intravenously every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg intravenously every 3 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC-FOLFOX
Description: Oxaliplatin 130 mg/m² via hepatic arterial infusion over 3 hours Leucovorin 400 mg/m² via hepatic arterial infusion over 2 hours Fluorouracil 400 mg/m² bolus via hepatic arterial infusion at hour 5, followed by 2400 mg/m² continuous hepatic arterial infusion over 46 hours HAIC treatment repeats every 3 weeks for up to 6 cycles
Study: NCT06742723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat/dapagliflozin
Description: baxdrostat tablet~dapagliflozin tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/dapagliflozin
Description: dapagliflozin tablet~placebo tablet
Study: NCT04853797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: 20 min infusion of 1 mg Levcromakalim followed by either oral Ivabradine or Placebo.
Study: NCT06041334

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Collection of a urine sample
Description: Collection of a urine sample for analysis of urinary biomarkers and urinary metabolomics (Inclusion and 1 year)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Imaging of the bladder
Description: Magnetic Resonance Imaging of the bladder (10 adults patients only) (Inclusion and 1 year)
Study: NCT06366113

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation includes :~* Exercise re-training with resumption of physical activities~* therapeutic patient education

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation includes :~* Exercise re-training with resumption of physical activities~* therapeutic patient education
Study: NCT05332756

Intervention type: OTHER
Intervention: Conservative management
Description: Patients and their first-degree relatives will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
Study: NCT04853797

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levcromakalim
Description: 20 min infusion of 1 mg Levcromakalim followed by either oral Ivabradine or Placebo.
Study: NCT05399446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Body Project
Description: The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Group
Description: We selected a T1D management/Eating disorder psychoeducational comparison condition to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
Study: NCT04028479

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker Testing (L)
Description: Patients who have received biomarker testing that could affect prognosis or treatment decisions. This generally excludes testing done to assist in the diagnosis of disease or histology where there is no treatment implication from this testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker Testing (L)
Description: Patients who have received biomarker testing that could affect prognosis or treatment decisions. This generally excludes testing done to assist in the diagnosis of disease or histology where there is no treatment implication from this testing.

Intervention type: DRUG
Intervention: Systemic Treatment (T)
Description: Patients who have received any treatment as part of their care. This refers to systemic treatment, but also allows other non-drug related interventions such as surgery or radiotherapy as part of the longitudinal care of the patient.

Intervention type: DRUG
Intervention: Systemic Treatment (T)
Description: Patients who have received any treatment as part of their care. This refers to systemic treatment, but also allows other non-drug related interventions such as surgery or radiotherapy as part of the longitudinal care of the patient.

Intervention type: OTHER
Intervention: Patient Reported Outcomes (P)
Description: Patients who have provided information about their disease, treatment course, or experience directly to the study using a patient facing tool or device.
Study: NCT05649956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg PO daily
Study: NCT05175885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ex vivo normothermic perfusion
Description: Ex vivo normothermic perfusion (EVNP) of the renal graft with the Ark Kidney System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold preservation
Description: Static cold storage (SCS) or hypothermic machine perfusion (HMP) of the renal graft
Study: NCT04889911

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coordinated Specialty Care
Description: Coordinated Specialty Care is an evidence-based, multimodal intervention for persons who have experienced a first episode of psychosis.
Study: NCT04853797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: 15 mg oral Ivabradine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo (calcium supplements).
Study: NCT04889911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated Specialty Care
Description: Coordinated Specialty Care is an evidence-based, multimodal intervention for persons who have experienced a first episode of psychosis.
Study: NCT06034652

Intervention type: DEVICE
Intervention: Integra® Gentrix® Surgical Matrix
Description: Integra® Gentrix® Surgical Matrix is intended for implantation to reinforce soft tissue where weakness exists in patients requiring gastroenterological or plastic \& reconstructive surgery.
Study: NCT04920123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-World
Description: Neuro-World is a collection of six games that are developed for cognitive training that focuses on memory and attention.
Study: NCT06493071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcutaneous Auricular Vagus Nerve Stimulation
Description: Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the tVNS R device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Parameters will be set for the duration of the intervention consisting of 4 hours of daily stimulation for a period of 30 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Auricular Vagus Nerve Stimulation
Description: Stimulation will target the ear lobe using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Participants will perform 4 hours of stimulation per day for a period of 30 days. Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
Study: NCT06329297

Intervention type: DEVICE
Intervention: CGM monitor
Description: blood glucose sensor used to monitor interstitial glucose

Intervention type: DEVICE
Intervention: CGM monitor
Description: blood glucose sensor used to monitor interstitial glucose
Study: NCT06035198

Intervention type: OTHER
Intervention: Stroke
Description: No intervention
Study: NCT05145439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VibratoSleeve Therapeutic Ultrasound Device
Description: The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf.
Study: NCT05031832

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV test
Description: HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status
Study: NCT06350877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: The physical activity intervention will be a 6-week supervised program. Participation will involve engaging in a weekly 1-h session provided in-person at the campus athletics and recreation centre. Each 1-h session will include: (1) 30 min of behaviour change coaching; and (2) 30 min of supervised and structured physical activity training. The intervention materials will include a behaviour change workbook for facilitating the 30 min of behaviour change coaching. Each week participants will complete the behaviour change workbook in session with the program trainer, whereby the overarching goal is to introduce and reinforce engagement in behaviour change techniques and to facilitate the learning objectives and experiences for each weekly session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: The physical activity intervention will be a 6-week supervised program. Participation will involve engaging in a weekly 1-h session provided in-person at the campus athletics and recreation centre. Each 1-h session will include: (1) 30 min of behaviour change coaching; and (2) 30 min of supervised and structured physical activity training. The intervention materials will include a behaviour change workbook for facilitating the 30 min of behaviour change coaching. Each week participants will complete the behaviour change workbook in session with the program trainer, whereby the overarching goal is to introduce and reinforce engagement in behaviour change techniques and to facilitate the learning objectives and experiences for each weekly session.
Study: NCT05860348

Intervention type: DEVICE
Intervention: Barostim™ System
Description: Implantation of the Barostim™ System
Study: NCT06653777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib will be administered orally once daily for 2 weeks followed by a 1-week off (intermittent schedule 2/1).
Study: NCT06653153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remternetug
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06420466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted Feeding
Description: Controlling the eating time to 6 hours per day, but not being prescriptive about the quantity and content of dietary intake.
Study: NCT06740318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Description: The intervention consists of three motivational interviews with the focus to enhance the participants motivation to enter treatment of alcohol use disorder. the interviews are structured and based on the model Motivational enhancement therapy.
Study: NCT05707065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core strengthening exercises
Description: The core muscles training includes transverse abdominis, multifidus, paraspinals, quadratus lumborum, and obliques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: lower limb PNF technique along with conventional treatment i.e., Rhythmic initiation, slow reversal, stabilizing reversal, and combination of isotones.
Study: NCT06320951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat 10 MG
Description: The subject will be randomized, in a double-blind manner to vericiguat 10 mg once daily for a period of 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will be randomized, in a double-blind manner to placebo once daily for a period of 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Sensitivity Test
Description: An assessment of the insulin sensitivity will be done using the Euglycemic Hyperinsulinemic Clamp, at baseline and after 12 weeks of pharmacological interventions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Sensitivity Test
Description: An assessment of the insulin sensitivity will be done using the Euglycemic Hyperinsulinemic Clamp, at baseline and after 12 weeks of pharmacological interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting Energy and Exercise Energy Expenditure Assessment
Description: Each participant's Energy Expenditure will be determined using a metabolic cart, at baseline and after 12 weeks of pharmacological interventions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resting Energy and Exercise Energy Expenditure Assessment
Description: Each participant's Energy Expenditure will be determined using a metabolic cart, at baseline and after 12 weeks of pharmacological interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Adipose Tissue Biopsy
Description: Participants who consent to participate in the exploratory aim will undergo WAT biopsy to assess UCP1 gene expression from the collected biospecimens, at baseline and after 12 weeks of pharmacological interventions.
Study: NCT06738043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: A bolus dose of dexmedetomidine (0.5 µg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.5 µg/kg/h until 10 minutes before the end of surgery.
Study: NCT06566521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic paravertebral block
Description: After surgery and before extubation, the patient was positioned in an upper lateral position on the affected side. For patients in the TPVB group, an ultrasound high-frequency linear array probe was used to perform a mid-sagittal scan at the T8-9 spinous process interspace on the affected side. The probe was moved to visualize the T8-9 transverse process and pleura. Using the out-of-plane needling technique, the needle was inserted between the costotransverse ligament and the pleura in the paravertebral space adjacent to the thoracic vertebra. After confirmation of no blood or cerebrospinal fluid return, 30 mL of 0.5% ropivacaine hydrochloride was injected. Under ultrasound guidance, the spread of the medication and downdraft of the pleura could be observed.
Study: NCT06320951

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White Adipose Tissue Biopsy
Description: Participants who consent to participate in the exploratory aim will undergo WAT biopsy to assess UCP1 gene expression from the collected biospecimens, at baseline and after 12 weeks of pharmacological interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI-PET Scan for Brown Adipose Tissue Volume Assessment
Description: Participants who consent to participate in the exploratory aim will undergo PET/MR to BAT volume at baseline and after 12 weeks of pharmacological interventions.
Study: NCT06649266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD1016
Description: RBD1016, active drug.
Study: NCT06320951

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI-PET Scan for Brown Adipose Tissue Volume Assessment
Description: Participants who consent to participate in the exploratory aim will undergo PET/MR to BAT volume at baseline and after 12 weeks of pharmacological interventions.
Study: NCT04982913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC116094
Description: Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC116094
Description: Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
Study: NCT06289517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Her2-affibody
Description: 68Ga-Her2-affibody is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Study: NCT06738043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Description: A bolus dose of ketamine (0.3 mg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.3 mg/kg/h until 10 minutes before the end of surgery.
Study: NCT05238740

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ViviGen®
Description: It will investigate the radiological and clinical outcome of ALIF procedure L5/S1 and XLIF L4/L5 procedure using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rhBMP-2
Description: It will investigate the radiological and clinical outcome of ALIF procedure L5/S1 and XLIF L4/L5 procedure using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
Study: NCT05533411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study: NCT06203951

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert® CT/NG and TV testing
Description: Participants randomized to universal STI testing will be offered Xpert® CT/NG and TV testing regardless of symptoms, and they will receive a standard syndromic STI assessment. Participants randomized to the asymptomatic only testing will be offered Xpert® CT/NG and TV testing if no signs or symptoms of CT, NG, or TV are identified during STI assessment. Participants assigned to receive Xpert® testing will be counseled on CT/NG/TV testing, including the benefits of testing even in the absence of symptoms to detect asymptomatic infections (as informed by pilot evaluation). If a client accepts Xpert® testing, she will be instructed by the study nurse on how to self-collect a vaginal swab.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert® CT/NG and TV testing
Description: Participants randomized to universal STI testing will be offered Xpert® CT/NG and TV testing regardless of symptoms, and they will receive a standard syndromic STI assessment. Participants randomized to the asymptomatic only testing will be offered Xpert® CT/NG and TV testing if no signs or symptoms of CT, NG, or TV are identified during STI assessment. Participants assigned to receive Xpert® testing will be counseled on CT/NG/TV testing, including the benefits of testing even in the absence of symptoms to detect asymptomatic infections (as informed by pilot evaluation). If a client accepts Xpert® testing, she will be instructed by the study nurse on how to self-collect a vaginal swab.
Study: NCT06253572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Educational Skills Program Based on Constructivist Learning Approach~Instructors need to receive training to improve their teaching skills during their graduate education and after their appointment as instructors. In this study, it is aimed to design and implement an Educational Skills Program based on the Constructivist Learning Approach. The design of the training program was based on the Dick, Carey and Carey (DCC) Instructional Design Model, which is widely known among instructional design models and influenced by constructivism theory. It is aimed that the training skills training program will be carried out by taking adult education into consideration and will be learner-centered. In this study, the training plan is based on the Constructivist Learning Approach 5E model, which is proven to be effective in the literature and widely used. The training program will be conducted through distance education to reach instructors living in different cities and to create common time.
Study: NCT06571747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular-Focused Nudge Communication
Description: Intervention arms will receive a behavioral economic rooted nudge communication highlighting the potential cardiovascular benefits of vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular-Focused Nudge Communication
Description: Intervention arms will receive a behavioral economic rooted nudge communication highlighting the potential cardiovascular benefits of vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular-Focused Nudge Communication
Description: Intervention arms will receive a behavioral economic rooted nudge communication highlighting the potential cardiovascular benefits of vaccination.